2 / 7
Page 72
Notes:
conference
series
.com
Volume 6, Issue 5 (Suppl)
OMICS J Radiol, an open access journal
ISSN: 2167-7964
Radiology and Oncology 2017
October 19-20, 2017
World Congress on
October 19-20, 2017 | New York, USA
Radiology and Oncology
Atorvastatin attenuate radiation-induced small intestine damage through downregulation of inflammation-
related molecules
Ching-Hsueh Cheng
1
, Ming-Feng Wei,
1,2
and Sung-Hsin Kuo
1,2
1
National Taiwan University Hospital, Taiwan
2
National Taiwan University College of Medicine, Taiwan
C
onsidering that the underlying characteristics of rapid cell turnover of small intestine epithelial cells, radiotherapy often resulted
in small intestine injury, such as apoptosis of epithelium and shortening of villi, when radiotherapy was used for treating
abdominal or pelvic cancer. Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is widely used in the
clinic for decreasing serum cholesterol. In addition, atorvastatin has many biological effects, including improvements of endothelial
function, and reductions of oxidative stress and inflammation. To avoid radiation-induced enteritis, we sought to investigate whether
atorvastatin can attenuate radiation-induced early and delayed damage of small intestine. In the present study, C57BL/6 mice were
divided into 4 groups: Control; Atorvastatin alone: 30 mg/kg atorvastatin was administered once daily for 5 days; Irradiation (IR)
alone: radiation at a dose of 5 Gy was administered once daily for 3 days (abdomen cavity) and Atorvastatin+IR: radiation of 5 Gy
was administered once daily for 3 days following administration of atorvastatin for 5 days. The results of the hematology (white blood
cells, platelet, and hemoglobin) and biochemical tests (albumin, alanine aminotransferase, creatinine, and lactic dehydrogenase)
showed that atorvastatin didn’t induce significant difference in mice with IR and Atorvastatin+IR groups. The value of Chiu’s injury
score and crypt/villi (C/V) ratio were used to assess mucosa damage level, and the results showed that administration of atorvastatin
decreased the damage level of atorvastatin+IR group (Chiu’s score: 0.67±0.58; C/V ratio: 0.50±0.07) when compared with IR alone
group (Chiu’s score: 3.67±0.58; C/V ratio: 1.11±0.14). Furthermore, the activation of IR-induced apoptosis-associated caspase 3
was also reduced after pretreatment of atorvastatin. Furthermore, atorvastatin down-regulated the mRNA levels of inflammatory
molecules, including IL-1α, IL-6, MMP9, NF-κB, Pin1, and TGF-β1 and the levels of fibrosis factor, including collage I and III. In
conclusion, atorvastatin can decrease the level of apoptosis, inflammation, and fibrogenesis of small intestine tissue after abdominal
radiotherapy.
Biography
Ching-Hsueh Cheng has received his BS degree in Medical Imaging and Radiological Sciences at Chung Shan Medical University, Taichung, Taiwan (ROC). He has re-
ceived his MS degree in Anatomy and Cell Biology from National Taiwan University of Medicine, Taipei, Taiwan in 2012. He has served as a Radiation Technician at Division
of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, since Aug 2012. His work contents included pre-treatment simulation,
linear accelerator (Varian and Elekta) operation, and Tomotherapy. His research focused on the research of combined radiation oncology with cell conduction and signaling
ryerson27575@gmail.comChing-Hsueh Cheng et al., OMICS J Radiol 2017, 6:5 (Suppl)
DOI: 10.4172/2167-7964-C1-016